MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy…
$0.15+3.40%
报价 2026-11-16
市值
$14.2M
EV
$107.1M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -96.4%
$0.14$4.15
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Diagnostics & Research| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MDXHMDxHealth S.A. | $14.2M | +3.4% | – | 57.6% | – | – | – | |
| PRPOPrecipio, Inc. | $35.8M | -9.8% | +23.7% | 43.7% | – | 66.7x | 50.4x | |
| STRRStar Equity Holdings, Inc. | $34.6M | -5.6% | +35.4% | 41.7% | – | – | – | |
| BNRBurning Rock Biotech Limited | $14M | -4.1% | – | 74.6% | – | – | – | |
| QUCYMainz Biomed N.V. | $13.5M | -6.4% | – | 80% | – | – | – | |
| BNGOBionano Genomics, Inc. | $13.1M | -6.0% | +13.0% | 47.5% | – | – | – | |
| BIAFbioAffinity Technologies, Inc. | $12.6M | -9.1% | +19.7% | -39.6% | – | – | – | |
| DRIODarioHealth Corp. | $11.3M | -8.7% | +17.4% | 56.1% | 3.5x | – | – | |
| NDRAENDRA Life Sciences Inc. | $6.6M | +0.2% | 0.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +18.5% | 45.6% | 3.5x | 66.7x | 50.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。